Synvista Therapeutics, Inc.
SYNI
Other OTC0.00
USD
-0.08
- -
ISIN
US87164M1009
CUSIP
87164M100
Return %
Stock
S&P500
1Y
- -
18.21
3Y
-99.00
63.29
5Y
-99.50
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 221 West Grand Avenue Parsippany United States of America
- IPO Date
- Jan 3, 2000
- Similar Companies
- Business
- Synvista Therapeutics, Inc. (NYSE American: SYNI) is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative diseases associated with protein misfolding and inflammation, including glaucoma and geographic atrophy. The company offers a pipeline of product candidates targeting these conditions, such as SY-307, a small molecule ROCK inhibitor in clinical development for glaucoma; SY-5001, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration; and preclinical programs including SY-501 for diabetic macular edema and SY-6001 for other retinal diseases. Synvista operates in the biopharmaceutical industry, serving patients and healthcare providers through clinical trials and potential commercialization in the United States and internationally. Founded in 2021 as a spin-out from Cognition Therapeutics and headquartered in New York, New York, Synvista Therapeutics targets the ophthalmology and neurodegeneration segments with its proprietary discovery platform. The company expanded its geographic operations through clinical trial sites across North America and Europe. It maintains independence without notable subsidiaries or parent relationships. In the last two years, Synvista Therapeutics completed its initial public offering in February 2025, raising approximately $7.4 million to advance its pipeline; announced positive topline results from the Phase 2 ROCKI trial of SY-307 in September 2025, demonstrating significant intraocular pressure reduction; and initiated dosing in the Phase 1/2 AETHERA trial for SY-5001 in November 2025. Additionally, the company forged a strategic collaboration with a leading contract research organization for trial execution and expanded its board with industry experts to support commercialization efforts. These developments position Synvista for accelerated growth in retinal disease treatments.